Ferrarese, R., A. Izzo, G. Andrieux, S. Lagies, J. P. Bartmuss, A. P. Masilamani, A. Wasilenko, D. Osti, S. Faletti, R. Schulzki, S. Yuan, E. Kling, V. Ribecco, D. H. Heiland, S. Tholen, Prinz, G. Pelicci, B. Kammerer, M. Boerries, and M. S. Carro. 2023. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma. Life Sci Alliance 6: e202201400. doi: 10.26508/lsa.202201400.
Locatelli, G., F. Marques-Ferreira, A. Katsoulas, V. Kalaitzaki, M. Krueger, B. Ingold-Heppner, S. Walthert, R. Sankowski, O. Prazeres da Costa, A. Dolga, M. Huber, M. Gold, C. Culmsee, A. Waisman, I. Bechmann, V. Milchevskaya, M. Prinz, A. Tresch, B. Becher, and T. Buch. 2022. IGF1R expression by adult oligodendrocytes is not required in the steady-state but supports neuroinflammation. Glia. doi: 10.1002/glia.24299. doi: 10.1002/glia.24299.
Carvalho LAR, Ross B, Fehr L, Bolgi O, Wöhrle S, Lum KM, Podlesainski D, Vieira AC, Kiefersauer R, Félix R, Rodrigues T, Lucas SD, Groß O, Geiss-Friedlander R, Cravatt BF, Huber R, Kaiser M, Moreira R. 2022. Chemoproteomics-Enabled Identification of 4-Oxo-β-Lactams as Inhibitors of Dipeptidyl Peptidases 8 and 9. Angew Chem Int Ed Engl. 61(47):e202210498. doi: 10.1002/anie.202210498.
Krausz, M., N. Mitsuiki, V. Falcone, J. Komp, S. Posadas-Cantera, H. M. Lorenz, J. Litzman, D. Wolff, M. Kanariou, A. Heinkele, C. Speckmann, G. Hacker, H. Hengel, L. Gamez-Diaz, and B. Grimbacher. 2022. Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency? Front Immunol 13: 1011646. doi: 10.3389/fimmu.2022.1011646.
Globig, A. M., V. Strohmeier, R. Surabattula, D. J. Leeming, M. A. Karsdal, M. Heeg, G. Kindle, S. Goldacker, C. von Spee-Mayer, M. Proietti, B. Bausch, D. Bettinger, M. Schultheiss, R. Thimme, D. Schuppan, and K. Warnatz. 2022. Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency. J Clin Immunol. pii: 10.1007/s10875-022-01319-0. doi: 10.1007/s10875-022-01319-0.
Gruninger, P. K., F. Uhl, H. Herzog, G. Gentile, M. Andrade-Martinez, T. Schmidt, K. Han, D. W. Morgens, M. C. Bassik, M. L. Cleary, O. Gorka, R. Zeiser, O. Gross, and J. Duque-Afonso. 2022. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. Cancer Gene Ther. pii: 10.1038/s41417-022-00491-0. doi: 10.1038/s41417-022-00491-0.
Carvalho, L. A. R., B. Ross, L. Fehr, O. Bolgi, S. Wohrle, K. M. Lum, D. Podlesainski, A. C. Vieira, R. Kiefersauer, R. Felix, T. Rodrigues, S. D. Lucas, O. Gross, R. Geiss-Friedlander, B. F. Cravatt, R. Huber, M. Kaiser, and R. Moreira. 2022. Chemoproteomics-Enabled Identification of 4-Oxo-beta-Lactams as Inhibitors of Dipeptidyl Peptidases 8 and 9. Angew Chem Int Ed Engl 61: e202210498. doi: 10.1002/anie.202210498.
Bauer, J., N. Kohler, Y. Maringer, P. Bucher, T. Bilich, M. Zwick, S. Dicks, A. Nelde, M. Dubbelaar, J. Scheid, M. Wacker, J. S. Heitmann, S. Schroeder, J. Rieth, M. Denk, M. Richter, R. Klein, I. Bonzheim, J. Luibrand, U. Holzer, M. Ebinger, I. B. Brecht, M. Bitzer, M. Boerries, J. Feucht, H. R. Salih, H. G. Rammensee, S. Hailfinger, and J. S. Walz. 2022. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 13: 6401. doi: 10.1038/s41467-022-33746-3.
Strohmeier, V., G. Andrieux, S. Unger, A. Pascual-Reguant, A. Klocperk, M. Seidl, O. C. Marques, M. Eckert, K. Grawe, M. Shabani, C. von Spee-Mayer, D. Friedmann, I. Harder, S. Gutenberger, B. Keller, M. Proietti, A. Bulashevska, B. Grimbacher, J. Provaznik, V. Benes, S. Goldacker, C. Schell, A. E. Hauser, M. Boerries, P. Hasselblatt, and K. Warnatz. 2022. Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. J Clin Immunol. pii: 10.1007/s10875-022-01379-2. doi: 10.1007/s10875-022-01379-2.
Petric, P. P., J. King, L. Graf, A. Pohlmann, M. Beer, and M. Schwemmle. 2022. Increased Polymerase Activity of Zoonotic H7N9 Allows Partial Escape from MxA. Viruses 14: 2331. doi: 10.3390/v14112331.
Konig, S., M. Fliegauf, M. Rhiel, B. Grimbacher, T. I. Cornu, T. Cathomen, and C. Mussolino. 2022. Allele-Specific Disruption of a Common STAT3 Autosomal Dominant Allele Is Not Sufficient to Restore Downstream Signaling in Patient-Derived T Cells. Genes (Basel) 13: pii: genes13101912. doi: 10.3390/genes13101912.
Leiding, J. W., T. P. Vogel, V. G. J. Santarlas, R. Mhaskar, M. R. Smith, A. Carisey, A. Vargas-Hernandez, M. Silva-Carmona, M. Heeg, A. Rensing-Ehl, B. Neven, J. Hadjadj, S. Hambleton, T. Ronan Leahy, K. Meesilpavikai, C. Cunningham-Rundles, C. M. Dutmer, S. O. Sharapova, M. Taskinen, I. Chua, R. Hague, C. Klemann, L. Kostyuchenko, T. Morio, A. Thatayatikom, A. Ozen, A. Scherbina, C. S. Bauer, S. E. Flanagan, E. Gambineri, L. Giovannini-Chami, J. Heimall, K. E. Sullivan, E. Allenspach, N. Romberg, S. G. Deane, B. T. Prince, M. J. Rose, J. Bohnsack, T. Mousallem, R. Jesudas, M. M. D. Santos Vilela, M. O’Sullivan, J. Pachlopnik Schmid, S. Pruhova, A. Klocperk, M. Rees, H. Su, S. Bahna, S. Baris, L. M. Bartnikas, A. Chang Berger, T. A. Briggs, S. Brothers, V. Bundy, A. Y. Chan, S. Chandrakasan, M. Christiansen, T. Cole, M. C. Cook, M. M. Desai, U. Fischer, D. A. Fulcher, S. Gallo, A. Gauthier, A. R. Gennery, J. Goncalo Marques, F. Gottrand, B. Grimbacher, E. Grunebaum, E. Haapaniemi, S. Hamalainen, K. Heiskanen, T. Heiskanen-Kosma, H. M. Hoffman, L. I. Gonzalez-Granado, A. L. Guerrerio, L. Kainulainen, A. Kumar, M. G. Lawrence, C. Levin, T. Martelius, O. Neth, P. Olbrich, A. Palma, N. C. Patel, T. Pozos, K. Preece, S. O. Lugo Reyes, M. A. Russell, Y. Schejter, C. Seroogy, J. Sinclair, E. Skevofilax, D. Suan, D. Suegeorgz, P. Szabolcs, H. Velasco, K. Warnatz, K. Walkovich, A. Worth, S. G. W. G. members, M. R. J. Seppanen, T. R. Torgerson, G. Sogkas, S. Ehl, S. G. Tangye, M. A. Cooper, J. D. Milner, and L. R. Forbes Satter. 2022. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome. J Allergy Clin Immunol. pii: S0091-6749(22)01182-4. doi: 10.1016/j.jaci.2022.09.002.
Schutze, K., M. Gross, K. Cornils, K. Wustrau, S. Schneppenheim, H. Lenhartz, G. C. Korenke, G. Janka, S. Ledig, I. Muller, S. Ehl, and K. Lehmberg. 2022. MAP kinase activating death domain deficiency is a novel cause of impaired lymphocyte cytotoxicity. Blood Adv. pii: 486738. doi: 10.1182/bloodadvances.2022008195.
Krausz, M., A. Uhlmann, I. C. Rump, G. Ihorst, S. Goldacker, G. Sogkas, S. Posadas-Cantera, R. Schmidt, M. Feisst, L. Alsina, I. Dybedal, M. Recher, Warnatz, and B. Grimbacher. 2022. The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial. Contemp Clin Trials Commun 30: 101008. doi: 10.1016/j.conctc.2022.101008.
Cook, J., and M. Prinz. 2022. Regulation of microglial physiology by the microbiota. Gut Microbes 14: 2125739. doi: 10.1080/19490976.2022.2125739.
Beer, J., S. Crotta, A. Breithaupt, A. Ohnemus, J. Becker, B. Sachs, L. Kern, M. Llorian, N. Ebert, F. Labroussaa, T. T. Nhu Thao, B. S. Trueeb, J. Jores, V. Thiel, M. Beer, J. Fuchs, G. Kochs, A. Wack, M. Schwemmle, and D. Schnepf. 2022. Impaired immune response drives age-dependent severity of COVID-19. J Exp Med 219: pii: 213485. doi: 10.1084/jem.20220621.